Immunome, Inc. (NASDAQ:IMNM) Shares Purchased by Wells Fargo & Company MN

Wells Fargo & Company MN lifted its stake in Immunome, Inc. (NASDAQ:IMNM) by 45.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 26,207 shares of the company’s stock after purchasing an additional 8,190 shares during the quarter. Wells Fargo & Company MN’s holdings in Immunome were worth $278,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. JPMorgan Chase & Co. grew its holdings in shares of Immunome by 2,540.4% during the fourth quarter. JPMorgan Chase & Co. now owns 648,610 shares of the company’s stock valued at $6,888,000 after buying an additional 624,045 shares during the last quarter. Barclays PLC grew its stake in Immunome by 125.9% during the 3rd quarter. Barclays PLC now owns 105,886 shares of the company’s stock valued at $1,547,000 after purchasing an additional 59,016 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Immunome in the fourth quarter valued at about $486,000. Scharf Investments LLC purchased a new position in shares of Immunome in the fourth quarter worth about $471,000. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Immunome during the fourth quarter worth about $379,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Guggenheim reduced their price target on shares of Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday, March 20th. Lifesci Capital assumed coverage on shares of Immunome in a report on Tuesday, March 11th. They set an “outperform” rating and a $20.00 target price for the company. Lake Street Capital assumed coverage on shares of Immunome in a report on Wednesday, April 2nd. They issued a “buy” rating and a $23.00 price target on the stock. Wedbush reiterated an “outperform” rating and set a $33.00 price objective on shares of Immunome in a research note on Thursday, March 20th. Finally, Stephens reissued an “overweight” rating and issued a $30.00 price objective on shares of Immunome in a report on Thursday, March 20th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $25.33.

Immunome Stock Performance

IMNM opened at $7.63 on Wednesday. The company has a fifty day moving average of $7.85 and a two-hundred day moving average of $10.04. The stock has a market capitalization of $663.90 million, a price-to-earnings ratio of -0.94 and a beta of 2.00. Immunome, Inc. has a fifty-two week low of $5.15 and a fifty-two week high of $16.81.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. The business had revenue of $2.74 million for the quarter, compared to analysts’ expectations of $3.07 million. On average, equities research analysts forecast that Immunome, Inc. will post -2.21 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Jean Jacques Bienaime acquired 7,000 shares of the firm’s stock in a transaction on Monday, March 24th. The shares were bought at an average price of $8.21 per share, for a total transaction of $57,470.00. Following the acquisition, the director now owns 23,615 shares of the company’s stock, valued at approximately $193,879.15. This trade represents a 42.13 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CTO Philip Tsai bought 12,300 shares of the company’s stock in a transaction dated Monday, March 24th. The shares were acquired at an average cost of $8.42 per share, with a total value of $103,566.00. Following the acquisition, the chief technology officer now directly owns 33,300 shares of the company’s stock, valued at approximately $280,386. This represents a 58.57 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 156,400 shares of company stock worth $1,160,495. Company insiders own 8.60% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.